COLLEGE STATION, Texas, July 6, 2026
Matica Biotechnology, Inc. (Matica Bio) has entered into a strategic partnership with VaxDome Inc. to accelerate the development and clinical advancement of a next-generation antigen-agnostic antiviral-vaccine hybrid platform designed to provide broad protection against emerging viral threats. The collaboration will support the progression of VaxDome’s proprietary zIFV technology toward clinical trials, with Matica Bio providing comprehensive process development, analytical development, and production of both non-GMP and cGMP clinical materials at its advanced manufacturing facility in College Station, Texas. The innovative platform is initially being developed using influenza as a disease model, while also demonstrating potential applications against diverse known and unknown viral pathogens and even lung cancer. The partnership highlights the growing importance of advanced viral vector manufacturing and platform technologies in accelerating next-generation vaccine development and strengthening global preparedness for future infectious disease outbreaks through scalable, precision-driven biopharmaceutical manufacturing.
Antigen-Agnostic Vaccine Platform Aims to Combat Emerging Viral Threats
At the heart of the collaboration is VaxDome’s proprietary zIFV (antiviral-vaccine hybrid) platform, an innovative technology designed to transform selected influenza virus strains into safe intranasal antiviral-vaccine candidates capable of generating broad immune protection regardless of viral mutations or antigenic variation. Unlike conventional vaccines that target specific viral antigens, the antigen-agnostic approach seeks to stimulate both innate and adaptive immune responses, enabling protection against a broad spectrum of evolving pathogens without requiring prior identification of viral genomes or future mutations.
In addition to its infectious disease applications, the platform has demonstrated promising potential in lung cancer, where it may promote the rapid formation of tertiary lymphoid structures within tumors while helping mitigate lymphopenia, creating opportunities for innovative cancer immunotherapy strategies. This differentiated scientific approach positions the platform as a promising candidate for addressing future pandemic threats and expanding therapeutic options beyond traditional vaccine technologies.
Matica Bio Provides End-to-End CDMO Expertise for Clinical Development
Advertisement
Under the agreement, Matica Bio will oversee the complete manufacturing workflow, including process optimization, analytical assay development, technology transfer, and production of clinical-grade materials required for future human studies. Leveraging its purpose-built cGMP manufacturing facility, the company will integrate advanced single-use bioprocessing technologies, inline process monitoring, and its proprietary MatiMax™ cell line technologies to ensure efficient scale-up from early development through clinical manufacturing.
Matica Bio’s extensive expertise across viral vector platforms, including adeno-associated virus (AAV), lentiviral vectors, and oncolytic viruses, provides the technical foundation needed to support VaxDome’s highly specialized antiviral-vaccine hybrid technology. By managing every stage of manufacturing under one roof, the collaboration is expected to streamline development timelines, maintain product consistency, and ensure compliance with stringent regulatory standards required for clinical evaluation while reducing manufacturing complexity for next-generation biologics.
Strategic Collaboration Advances Innovation in Vaccine and Biopharmaceutical Development
The partnership reinforces the growing role of contract development and manufacturing organizations (CDMOs) in accelerating innovation across the global biopharmaceutical industry. As emerging infectious diseases continue to challenge healthcare systems worldwide, adaptable vaccine technologies capable of responding rapidly to new viral threats are becoming increasingly valuable. By combining VaxDome’s breakthrough antigen-agnostic vaccine platform with Matica Bio’s advanced manufacturing capabilities, the collaboration aims to accelerate clinical translation while supporting scalable production for future global development.
The alliance also reflects increasing industry investment in platform-based vaccine technologies, precision manufacturing, and integrated development models capable of shortening timelines from laboratory discovery to clinical application. As both organizations continue advancing this innovative program, the collaboration has the potential to contribute to future pandemic preparedness, precision immunology, and next-generation vaccine innovation, while opening new opportunities for treating infectious diseases and oncology through versatile viral platform technologies.
Source: Matica Bio, VaxDome press release
